- Company
- Jemperli expands indication to all endometrial cancers
- by Whang, byung-woo Dec 11, 2024 05:52am
- Jemperli's (dostarlimab) indication was expanded to include its use as a first-line treatment in combination with platinum-based chemotherapy for all patients with advanced or recurrent endometrial cancer. The drug is expected to further expand its influence, with the Health Insurance Review and Assessment Service's Cancer Disease Deliberati
- Company
- MM drug Revlimid continues to thrive after patent expiry
- by Eo, Yun-Ho Dec 11, 2024 05:52am
- Sales of the multiple myeloma drug Revlimid continue to thrive even after patent expiry in Korea. According to industry sources, Bristol Myers Squibb Korea’s Revlimid (lenalidomide) still boasts its originality with an 80% market share. As of Q3 2024 (IQVIA), Revelimid's sales were KRW 11.2 billion, significantly outpacing the sales
- Company
- Antibiotic clarithromycin market grows fourfold in 3 yrs
- by Chon, Seung-Hyun Dec 10, 2024 05:53am
- The prescription market for the antibiotic clarithromycin has significantly expanded. The market size grew by nearly fourfold over three years. Impurities-related cautions were once issued, but the volume of use increased during the COVID-19 pandemic and endemic period. According to a pharmaceutical market research firm UBIST on December 9, t
- Company
- 1st MET-targeting anticancer drug likely to get reimb in KOR
- by Eo, Yun-Ho Dec 10, 2024 05:53am
- The MET-targeting anticancer drug 'Tepmetko' has passed the review process for reimbursement listing three years after being approved in South Korea.. Sources said that Merck Korea's Tepmetko (tepotinib), a treatment for patients with topically advanced or metastatic non-small cell lung cancer (NSCLC) harboring mesenchymal-epithelial tran
- Company
- GC Biopharma&Dong-A ST research mRNA-LNP-based treatment
- by Kim, Jin-Gu Dec 10, 2024 05:52am
- On the 9th, GC Biopharma announced that it had signed a follow-up joint research agreement with Dong-A ST to develop mRNA-LNP-based new drugs for chronic inflammatory diseases The companies had jointly selected new drug targets for chronic inflammatory diseases in October last year after forging a collaboration agreement that covers the j
- Company
- ‘Pluvicto, a new standard therapy for prostate cancer?'
- by Whang, byung-woo Dec 10, 2024 05:52am
- Prostate cancer is one disease area where the treatment environment has been improving with the increasing number of treatment options listed for health reimbursement benefits. Recently, Pluvicto (vipivotide tetraxetan), a radioligand therapy with a new mechanism of action, has emerged and is attracting attention as a viable new standard of c
- Policy
- Cancellation policy for innovative pharmas certification
- by Kang, Shin-Kook Dec 9, 2024 05:47am
- It has been reported that the cancellation standards of 'Innovative Pharmaceutical Companies Certification' will be relaxed for pharmaceutical companies fined for rebates. Some argue that certification requirements for illegal rebates are strict. Further criticism is anticipated as these measures deviate from the government’s longstandin
- Company
- Padcev seeks reimb as mono and combo therapy in KOR
- by Eo, Yun-Ho Dec 9, 2024 05:47am
- The ADC bladder cancer drug Padcev is seeking reimbursement as both monotherapy and combination therapy in Korea. According to industry sources, Astellas Pharma Korea recently submitted reimbursement applications for Padcev (enfortumab vedotin) as monotherapy and combination therapy with PD-1 inhibitor Keytruda (pembrolizumab) in the trea
- Company
- New treatment options for pancreatic cancer arise
- by Son, Hyung Min Dec 9, 2024 05:47am
- New antibody drugs are showing results in pancreatic cancer, a disease area that has been regarded as an incurable disease. Recently, a new bispecific antibody drug from the Dutch company Merus was approved for the treatment of pancreatic cancer in the United States. In clinical trials, the drug has shown therapeutic effects in patients with pan
- Company
- Auto part company confirms potential of novel antibody drug
- by Son, Hyung Min Dec 9, 2024 05:46am
- Kumho HT's candidate product for cancer immunotherapy demonstrated drug tolerance and effectiveness in human-subject clinical trials. At the European Society for Medical Oncology (ESMO) Asia Congress 2024, held for three days from December 6, the Phase 1 clinical trial result of Kumho HT's DNP-002, a new anticancer drug, has been unveiled. Kumho
